Exendin-4 Modulates Diabetes Onset in Nonobese Diabetic Mice
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Activation of the glucagon-like peptide-1 receptor (GLP-1R) is associated with expansion of β-cell mass due to stimulation of cell proliferation and induction of antiapoptotic pathways coupled to β-cell survival. Although the GLP-1R agonist Exenatide (exendin-4) is currently being evaluated in subjects with type 1 diabetes, there is little information available about the efficacy of GLP-1R activation for prevention of experimental type 1 diabetes. We examined the consequences of exendin-4 (Ex-4) administration (100 ng once daily and 2 μg twice daily) on diabetes onset in nonobese diabetic mice beginning at either 4 or 9 wk of age prior to the onset of diabetes. Ex-4 treatment for 26 wk (2 μg twice daily) initiated at 4 wk of age delayed the onset of diabetes (P = 0.007). Ex-4-treated mice also exhibited a significant reduction in insulitis scores, enhanced β-cell mass, and improved glucose tolerance. Although GLP-1R mRNA transcripts were detected in spleen, thymus, and lymph nodes from nonobese diabetic mice, Ex-4 treatment was not associated with significant changes in the numbers of CD4+ or CD8+ T cells or B cells in the spleen. However, Ex-4 treatment resulted in an increase in the number of CD4+ and CD8+ T cells in the lymph nodes and a reduction in the numbers of CD4+CD25+Foxp3+ regulatory T cells in the thymus but not in lymph nodes. These findings demonstrate that sustained GLP-1R activation in the absence of concomitant immune intervention may be associated with modest but significant delay in diabetes onset in a murine model of type 1 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Studies to date that have reported an increase in β-cell mass with glucagon-like peptide 1 (GLP-1)-1 based therapies were undertaken in young rodents (17–21).”
From Age-Dependent Decline in β-Cell Proliferation Restricts the Capacity of β-Cell Regeneration in Mice (2009) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bradford, M. M. (1976) · Analytical Biochemistry · doi:10.1016/0003-2697(76)90527-3 · Cited by 255,302 · cited 1×
“Total protein levels in extracts were determined using the Bradford method (19) with dye reagent (Bio-Rad Laboratories, Inc.”
MethodDrucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 16×
“The cytoprotective and regenerative properties of GLP-1R agonists have raised the possibility that prolonged treatment of patients with T2DM using GLP-1R agonists such as exendin-4 (Exenatide) might be associated with preservation or enhancement of -cell mass, parameters that remain difficult to assess in human subjec…”
BackgroundResultInfluentialSelf-citationRegulatory T Cell Lineage Specification by the Forkhead Transcription Factor Foxp3
Fontenot, J. D., Rasmussen, J. P., Williams, L. M., Dooley, J. L., Farr, A. G., & Rudensky, A. Y. (2005) · Immunity · doi:10.1016/j.immuni.2005.01.016 · Cited by 2,279
International trial of the Edmonton protocol for islet transplantation
Shapiro, A. M. J., Ricordi, C., Hering, B. J., Auchincloss, H., Lindblad, R., Robertson, R. P., Secchi, A., Brendel, M. D., Berney, T., Brennan, D. C., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061267 · Cited by 1,942
Xu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209
Glucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis
Li, Y., Hansotia, T., Yusta, B., Ris, F., Halban, P. A., & Drucker, D. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209423200 · Cited by 589
Self-citationStoffers, D. A., Kieffer, T. J., Hussain, M. A., Drucker, D. J., Bonner-Weir, S., Habener, J. F., & Egan, J. M. (2000) · Diabetes · doi:10.2337/diabetes.49.5.741 · Cited by 576
Self-citationGlucagon-like peptide-1 prevents beta cell glucolipotoxicity
Joly, E., Prentki, M., Buteau, J., El-Assaad, W., Rhodes, C. J., & Rosenberg, L. (2004) · Diabetologia · doi:10.1007/s00125-004-1379-6 · Cited by 337
Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice
Wang, Q., & Brubaker, P. (2002) · Diabetologia · doi:10.1007/s00125-002-0828-3 · Cited by 312 · cited 1×
“GLP-1R agonists reduce -cell apoptosis in young db/db mice or in wild-type mice after administration of streptozotocin (8, 9).”
BackgroundDrucker, D. J. (2003) · Endocrinology · doi:10.1210/en.2003-1147 · Cited by 274
Self-citation
Research works printed but not linked: 1
- Masur K, Beinborn M, Zaenker KS 2004 Glucagon-like peptide-1 (GLP-1) is not only an important incretin hormone but also a modulator of the cellular immune system. Diabetes 53:A49-LB [Google Scholar]
Cited by
Pharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500
“Ex-4 (0.1–4 mg/day) delayed the onset of diabetes and reduced lymphocyte infiltration into the islets of female NOD mice when Ex-4 administration was started at 4 or 9 weeks of age (Hadjiyanni et al., 2008).”
BackgroundInfluentialSelf-citationType 1 Diabetes: Etiology, Immunology, and Therapeutic Strategies
Van Belle, T. L., Coppieters, K. T., & Von Herrath, M. G. (2011) · Physiological Reviews · doi:10.1152/physrev.00003.2010 · Cited by 1,022
“GLP-1 receptor activation modestly delayed diabetes onset in NOD mice (171).”
BackgroundThe role of incretins in glucose homeostasis and diabetes treatment
Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824
“GLP-1R mRNA transcripts have also been detected in spleen, thymus, and lymph nodes from nondiabetic and diabetic mice (Hadjiyanni et al., 2008).”
BackgroundGABA exerts protective and regenerative effects on islet beta cells and reverses diabetes
Soltani, N., Qiu, H., Aleksic, M., Glinka, Y., Zhao, F., Liu, R., Li, Y., Zhang, N., Chakrabarti, R., Ng, T., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1102715108 · Cited by 417
“The incretin hormone GLP-1 has demonstrated a β-cell stimulatory capacity and clinical efficacy in T2D treatment (6), but it is only marginally effective in T1D treatment (7), likely because of an insufficient effect of GLP-1 on the suppression of autoimmunity.”
BackgroundThe anti-inflammatory and immunological properties of GLP-1 Receptor Agonists
Bendotti, G., Montefusco, L., Lunati, M. E., Usuelli, V., Pastore, I., Lazzaroni, E., Assi, E., Seelam, A. J., El Essawy, B., Jang, J., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106320 · Cited by 406
Panjwani, N., Mulvihill, E. E., Longuet, C., Yusta, B., Campbell, J. E., Brown, T. J., Streutker, C., Holland, D., Cao, X., Baggio, L. L., et al. (2013) · Endocrinology · doi:10.1210/en.2012-1937 · Cited by 346
“RT-PCR analysis Mouse Glp1r mRNA analysis was performed as described (19).”
Self-citationAge-Dependent Decline in β-Cell Proliferation Restricts the Capacity of β-Cell Regeneration in Mice
Tschen, S.-I., Dhawan, S., Gurlo, T., & Bhushan, A. (2009) · Diabetes · doi:10.2337/db08-1651 · Cited by 331
Hogan, A. E., Tobin, A. M., Ahern, T., Corrigan, M. A., Gaoatswe, G., Jackson, R., O’Reilly, V., Lynch, L., Doherty, D. G., Moynagh, P. N., et al. (2011) · Diabetologia · doi:10.1007/s00125-011-2232-3 · Cited by 191
Suarez-Pinzon, W. L., Power, R. F., Yan, Y., Wasserfall, C., Atkinson, M., & Rabinovitch, A. (2008) · Diabetes · doi:10.2337/db08-0688 · Cited by 187
“GLP-1 was synthetic human GLP-1 [7-36] amide (Bachem, Torrance, CA).”
MethodHadjiyanni, I., Siminovitch, K. A., Danska, J. S., & Drucker, D. J. (2010) · Diabetologia · doi:10.1007/s00125-009-1643-x · Cited by 166
Self-citationKoehler, J. A., Kain, T., & Drucker, D. J. (2011) · Endocrinology · doi:10.1210/en.2011-1201 · Cited by 128
“4-kb product spanning bases 79–1486 of the GLP-1R open reading frame (16).”
BackgroundSelf-citationMinireview: Update on Incretin Biology: Focus on Glucagon-Like Peptide-1
Brubaker, P. L. (2010) · Endocrinology · doi:10.1210/en.2010-0115 · Cited by 122
GLP-1 receptor agonist as a modulator of innate immunity
Chen, J., Mei, A., Wei, Y., Li, C., Qian, H., Min, X., Yang, H., Dong, L., Rao, X., & Zhong, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.997578 · Cited by 120
“Glucagon-like peptide-1 (GLP-1) is an endogenous incretin secreted by small intestinal L cells, consisting of two bioactive isoforms: GLP-1 (7-37) and GLP-1 (736).”
BackgroundNever waste a good crisis: confronting reproducibility in translational research
Drucker, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.08.006 · Cited by 117
Self-citationSczelecki, S., Besse-Patin, A., Abboud, A., Kleiner, S., Laznik-Bogoslavski, D., Wrann, C. D., Ruas, J. L., Haibe-Kains, B., & Estall, J. L. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00578.2013 · Cited by 108
Kim, S.-J., Nian, C., Doudet, D. J., & McIntosh, C. H. S. (2009) · Diabetes · doi:10.2337/db08-1101 · Cited by 106
“However, exendin-4 treatment was not associated with significant changes in the number of CD4 and CD8 T-cells or B-cells in the spleen (51).”
BackgroundGlucagon-like peptide 1 receptor is a T cell-negative costimulatory molecule
Ben Nasr, M., Usuelli, V., Dellepiane, S., Seelam, A. J., Fiorentino, T. V., D’Addio, F., Fiorina, E., Xu, C., Xie, Y., Balasubramanian, H. B., et al. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.05.001 · Cited by 102
Diabetes resolution and hyperinsulinaemia after metabolic Roux‐en‐Y gastric bypass
Ashrafian, H., Athanasiou, T., Li, J. V., Bueter, M., Ahmed, K., Nagpal, K., Holmes, E., Darzi, A., & Bloom, S. R. (2011) · Obesity Reviews · doi:10.1111/j.1467-789x.2010.00802.x · Cited by 95
“Furthermore, the GLP-1 mimetic exenatide (86,159) (approved April 2005) has not to date been reported to result in nesidioblastosis in humans.”
BackgroundPAHSAs attenuate immune responses and promote β cell survival in autoimmune diabetic mice
Syed, I., de Celis, M. F. R., Mohan, J. F., Moraes‐Vieira, P. M., Vijayakumar, A., Nelson, A. T., Siegel, D. R., Saghatelian, A., Mathis, D. J., & Kahn, B. B. (2019) · Journal of Clinical Investigation · doi:10.1172/jci122445 · Cited by 93
“Exendin(9-39) alone attenuated MIN6 cell viability by 16% compared with DMSO control.”
BackgroundMethodResultInfluentialYap, M. K. K., & Misuan, N. (2019) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13169 · Cited by 77
He, L., Wong, C. K., Cheung, K. K., Yau, H. C., Fu, A., Zhao, H., Leung, K. M., Kong, A. P., Wong, G. W., Chan, P. K., et al. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12063 · Cited by 70
Moschovaki Filippidou, F., Kirsch, A. H., Thelen, M., Kétszeri, M., Artinger, K., Aringer, I., Schabhüttl, C., Mooslechner, A. A., Frauscher, B., Pollheimer, M., et al. (2020) · The American Journal of Pathology · doi:10.1016/j.ajpath.2019.10.008 · Cited by 66
Self-citationGlucagon-like peptide-1 (GLP-1) receptor agonists, obesity and psoriasis: diabetes meets dermatology
Drucker, D. J., & Rosen, C. F. (2011) · Diabetologia · doi:10.1007/s00125-011-2297-z · Cited by 66
Self-citationIncreased expression of glucagon‐like peptide‐1 receptors in psoriasis plaques
Faurschou, A., Pedersen, J., Gyldenløve, M., Poulsen, S. S., Holst, J. J., Thyssen, J. P., Zachariae, C., Vilsbøll, T., Skov, L., & Knop, F. K. (2013) · Experimental Dermatology · doi:10.1111/exd.12081 · Cited by 63
Cui, Y., Elahi, D., & Andersen, D. K. (2011) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-011-1585-8 · Cited by 67
Pugazhenthi, U., Velmurugan, K., Tran, A., Mahaffey, G., & Pugazhenthi, S. (2010) · Diabetologia · doi:10.1007/s00125-010-1849-y · Cited by 61
Exenatide regulates Th17/Treg balance via PI3K/Akt/FoxO1 pathway in db/db mice
Xu, Q., Zhang, X., Li, T., & Shao, S. (2022) · Molecular Medicine · doi:10.1186/s10020-022-00574-6 · Cited by 65
Tian, B., Hao, J., Zhang, Y., Tian, L., Yi, H., O’Brien, T. D., Sutherland, D. E. R., Hering, B. J., & Guo, Z. (2009) · Transplantation · doi:10.1097/tp.0b013e3181933261 · Cited by 60
“A recent study showed that exendin-4 treatment could significantly delay diabetes onset in NOD mice beginning at 4 or 9 weeks of age before the onset of diabetes (33).”
BackgroundGABAergic regulation of pancreatic islet cells: Physiology and antidiabetic effects
Wang, Q., Ren, L., Wan, Y., & Prud’homme, G. J. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28214 · Cited by 62
The role of insulin signaling in the development of β-cell dysfunction and diabetes
Wang, Q., & Jin, T. (2009) · Islets · doi:10.4161/isl.1.2.9263 · Cited by 64
Treatment of Type 1 Diabetic Patients with Glucagon-Like Peptide-1 (GLP-1) and GLP-1R Agonists
Kielgast, U., Holst, J., & Madsbad, S. (2009) · Current Diabetes Reviews · doi:10.2174/157339909789804413 · Cited by 56
“development was delayed from age 21 to 29 weeks, and in all mice that had survived without diabetes until age 30 weeks, exendin-4 treated animals displayed significantly lower insulitis score, an increase in number of islets without infiltration and an increased ß-cell mass compared with saline treated animals [72].”
Hadjiyanni, I., Li, K. K., & Drucker, D. J. (2008) · Endocrinology · doi:10.1210/en.2008-1228 · Cited by 65
Self-citationKim, S.-J., Nian, C., & McIntosh, C. H. S. (2010) · Diabetes · doi:10.2337/db09-1618 · Cited by 54
“However, although activation of GLP-1 receptors was shown to modulate the number of thymic CD4 CD25 Foxp3 regulatory T-cells (11), we observed no effect of either GIP or GLP-1 on splenic or thymic CD4 T-cell migration in vitro (Fig.”
Exendin‐4 Therapy in NOD Mice with New‐Onset Diabetes Increases Regulatory T Cell Frequency
Xue, S., Wasserfall, C. H., Parker, M., Brusko, T. M., McGrail, S., McGrail, K., Moore, M., Campbell‐Thompson, M., Schatz, D. A., Atkinson, M. A., et al. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1447.049 · Cited by 51
Targeting Regulatory T Cells in the Treatment of Type 1 Diabetes Mellitus
Cabrera, S. M., Rigby, M. R., & Mirmira, R. G. (2012) · Current Molecular Medicine · doi:10.2174/156652412803833634 · Cited by 55
“In fact, GLP-1 stimulation delays diabetes development in NOD mice [103, 104] with the effect magnified when the GLP-1 receptor agonist is combined with the immunosuppressant therapies, such as anti-CD3 monoclonal antibody [105].”
BackgroundLiu, W., Son, D. O., Lau, H., Zhou, Y., Prud’homme, G. J., Jin, T., & Wang, Q. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00362 · Cited by 53
“, 2003), they showed very marginal therapeutic effects for T1D subjects in both humans and rodent models, possibly due to their restricted immune regulatory effects (Hadjiyanni et al., 2008; Pettus et al., 2013; Wan et al., 2015).”
BackgroundJelsing, J., Vrang, N., van Witteloostuijn, S. B., Mark, M., & Klein, T. (2012) · Journal of Endocrinology · doi:10.1530/joe-11-0479 · Cited by 52
“Among the proposed mechanisms underlying this effect are stimulation of cellular proliferation, inhibition of apoptosis and recovery of residual cellular mass (Hadjiyanni et al. 2008, Shimoda et al. 2011).”
Prevention of type 1 diabetes: the time has come
Sherr, J. L., Sosenko, J. M., Skyler, J. S., & Herold, K. C. (2008) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0832 · Cited by 51
Pozzilli, P., Bosi, E., Cirkel, D., Harris, J., Leech, N., Tinahones, F. J., Vantyghem, M.-C., Vlasakakis, G., Ziegler, A.-G., & Janmohamed, S. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa149 · Cited by 45
GLP-1 agonists in type 1 diabetes
Pettus, J., Hirsch, I. B., & Edelman, S. V. (2013) · Clinical Immunology · doi:10.1016/j.clim.2013.04.006 · Cited by 48
“Similarly, GLP-1 monotherapy was able to delay the onset of diabetes in mice treated at four weeks of age but not at nine weeks of age [27].”
BackgroundShao, S., Zhang, X., Xu, Q., Pan, R., & Chen, Y. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108270 · Cited by 46
Immunotherapy for the Prevention and Treatment of Type 1 Diabetes
Bresson, D., & von Herrath, M. (2009) · Diabetes Care · doi:10.2337/dc09-0373 · Cited by 42
Choi, J., Diao, H., Feng, Z., Lau, A. N., Wang, R., Jevnikar, A. M., & Ma, S. (2013) · Plant Biotechnology Journal · doi:10.1111/pbi.12149 · Cited by 37
“Ex-4 increased insulin production by b-cells in response to glucose, promoted b-cell regeneration and protected against apoptosis (Hadjiyanni et al., 2008; Lovshin and Drucker, 2009).”
BackgroundKedees, M. H., Guz, Y., Grigoryan, M., & Teitelman, G. (2013) · Peptides · doi:10.1016/j.peptides.2013.07.022 · Cited by 40
Time for Testing Incretin Therapies in Early Type 1 Diabetes?
Bosi, E. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2741 · Cited by 38
“to exenatide) showed a beneficial effect on -cell mass when administered together with anti-CD3 antibodies (3) oralonewithoutanyconcomitant immune intervention (4).”
BackgroundRegulation of Mouse Intestinal L Cell Progenitors Proliferation by the Glucagon Family of Peptides
Grigoryan, M., Kedees, M. H., Charron, M. J., Guz, Y., & Teitelman, G. (2012) · Endocrinology · doi:10.1210/en.2012-1120 · Cited by 34
Riedel, M. J., Gaddy, D. F., Asadi, A., Robbins, P. D., & Kieffer, T. J. (2009) · Gene Therapy · doi:10.1038/gt.2009.143 · Cited by 33
Degen, A., Krynytska, І., & Kamyshnyi, O. (2020) · Endocrine Regulations · doi:10.2478/enr-2020-0019 · Cited by 32
Pro-GLP-1, a Pro-drug of GLP-1, is neuroprotective in cerebral ischemia
Zhang, H., Meng, J., Li, X., Zhou, S., Qu, D., Wang, N., Jia, M., Ma, X., & Xiaoxing, L. (2015) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2015.01.010 · Cited by 28
“Our results are in accordance with previous reports (Hadjiyanni et al., 2008; Gao and Jusko, 2011; Li et al., 2012).”
ResultStanisavljević, I., Pavlovic, S. M., Marković, B. S., Jurišević, M., Krajnović, T., Mijatović, S., Spasojević, M., Mitrović, S., Corovic, I. F., & Jovanović, I. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117668 · Cited by 35
The potential of incretin-based therapies in type 1 diabetes
Suen, C. S., & Burn, P. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.08.017 · Cited by 30
“1), 447 36 Hadjiyanni, I. et al. (2008) Exendin-4 modulates diabetes onset in nonobese diabetic”
BackgroundCombination therapies in the context of anti-CD3 antibodies for the treatment of autoimmune diseases
Dean, Y. D., Dépis, F., & Kosco‐Vilbois, M. H. (2012) · Swiss Medical Weekly · doi:10.4414/smw.2012.13711 · Cited by 27
The role of incretins and incretin-based drugs in autoimmune diseases
Radbakhsh, S., Atkin, S. L., Simental‐Mendía, L. E., & Sahebkar, A. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107845 · Cited by 24
Benefits of healthy adipose tissue in the treatment of diabetes
Gunawardana, S. C. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i4.420 · Cited by 31
Bantle, A., Wang, Q., & Bantle, J. P. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1283 · Cited by 26
“Postprandial serum insulin and GLP-1 responses are known to increase after gastric bypass surgery (10–12), and GLP-1 has been shown to increase -cell mass in rodent models (13, 14).”
BackgroundFarnsworth, N. L., Walter, R., Piscopio, R. A., Schleicher, W. E., & Benninger, R. K. P. (2018) · The Journal of Physiology · doi:10.1113/jp276106 · Cited by 25
“2013), increases in Cx36 coupling may contribute to the mechanism by which E4 treatment protects against decline in islet mass in a mouse model of type 1 diabetes (Hadjiyanni et al. 2008).”
BackgroundYang, L., Yuan, J., & Zhou, Z. (2014) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2014.01.008 · Cited by 25
“The GLP-1 receptor is expressed in lymphoid tissue, and GLP-1 analogue exendin-4 (2 mg twice daily) treatment was shown to increase numbers of CD4þ and CD8þ T cells in lymph nodes and reduce the number of CD4þCD25þFoxp3þ regulatory T cells in the thymus, but not the spleen, suggesting specific effects on different sub…”
Pérez-Arana, G.-M., Blandino-Rosano, M., Oliveira, J. A. P., Aguilar‐Diosdado, M., & Segundo, C. (2010) · Endocrinology · doi:10.1210/en.2009-1113 · Cited by 21
Exenatide: A new promising antidiabetic agent
Chakraborti, C. (2010) · Indian Journal of Pharmaceutical Sciences · doi:10.4103/0250-474x.62228 · Cited by 21
“Activation of GLP-1 receptor is accompanied with expansion of beta-cell mass due to stimulation of cell proliferation and promotion of antiapoptotic pathways coupled with beta-cell survival[22].”
BackgroundXue, S., Wasserfall, C. H., Parker, M., McGrail, S., MCGRAIL, K. M., Campbell‐Thompson, M., Schatz, D., Atkinson, M. A., & Haller, M. J. (2009) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2008.12.004 · Cited by 22
An update on pancreatic regeneration mechanisms: Searching for paths to a cure for type 2 diabetes
Soldovieri, L., Giuseppe, G. D., Ciccarelli, G., Quero, G., Cinti, F., Brunetti, M., Nista, E. C., Gasbarrini, A., Alfieri, S., Pontecorvi, A., et al. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101754 · Cited by 20
“In particular, the increase in gut hormones post gastric bypass and the confirmed role of gut hormones in triggering b-cell neogenesis and proliferation while inhibiting apoptosis leads to islet cell hyperplasia in rodents [86,161], suggesting this as a possible pathogenetic mechanism of nesidioblastosis.”
BackgroundAnalgesic and anti-inflammatory effectiveness of sitagliptin and vildagliptin in mice
Újhelyi, J., Ujhelyi, Z., Szalai, A., László, J. F., Cayasso, M., Vecsernyés, M., & Pórszász, R. (2014) · Regulatory Peptides · doi:10.1016/j.regpep.2014.09.006 · Cited by 19
“It could also reduce the number of CD4+ CD25+ Foxp3 + regulatoryTcells in the thymus, but not in the spleen [31], thus playing a regulatory role in the immune system and can influence inflammatory processes [32].”
The role of incretin-based therapies in prediabetes: A review
Ahmadieh, H., & Azar, S. T. (2014) · Primary care diabetes · doi:10.1016/j.pcd.2014.02.005 · Cited by 24
Complete loss of insulin secretion capacity in type 1A diabetes patients during long‐term follow up
Uno, S., Imagawa, A., Kozawa, J., Fukui, K., Iwahashi, H., & Shimomura, I. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12763 · Cited by 19
Possible Role of GLP-1 and Its Agonists in the Treatment of Type 1 Diabetes Mellitus
Issa, C. M., & Azar, S. T. (2012) · Current Diabetes Reports · doi:10.1007/s11892-012-0291-6 · Cited by 15
Li, L., Lü, J., Jia, X., Hui, H., Zhang, J., Liu, Y. M., Cui, W., Xu, Q., & Zhu, D. (2016) · Molecular Medicine · doi:10.2119/molmed.2016.00168 · Cited by 15
Immunotherapies in Diabetes Mellitus Type 1
Gupta, S. (2012) · Medical Clinics of North America · doi:10.1016/j.mcna.2012.04.008 · Cited by 15
Mitochondrial-encoded peptide MOTS-c prevents pancreatic islet cell senescence to delay diabetes
Kong, B. S., Lee, H., L’Yi, S., Hong, S., & Cho, Y. M. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01521-1 · Cited by 16
Treatment of diabetes with glucagon-like peptide-1 gene therapy
Riedel, M. J., & Kieffer, T. J. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2010.532786 · Cited by 14
“For example, administration of GLP-1 or exendin4 alone to pre-diabetic NOD mice not only induces b-cell proliferation and neogenesis, but also suppresses b-cell apoptosis and delays the onset of type 1 diabetes [146,147].”
BackgroundDavanso, M. R., Caliári-Oliveira, C., Couri, C. E. B., Covas, D. T., Leal, A. M. O., Voltarelli, J. C., Malmegrim, K. C. R., & Yaochite, J. N. U. (2019) · Inflammation · doi:10.1007/s10753-018-00954-3 · Cited by 13
From pumps to prevention: recent advances in the treatment of type 1 diabetes
Sherr, J. L., Cengiz, E., & Tamborlane, W. V. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.06.011 · Cited by 16
Evaluation of Hypoglycemic and Antioxidative Effects of Synthesized Peptide MC 62
Yang, B., Chen, W., Jin, J., Mei, Y., Wang, X., Chen, H., Yan, S., Meng, R., Gu, G., Deng, X., et al. (2013) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12137 · Cited by 12
“03 μmol/kg, body weight) (11-13) intraperitoneally once daily for 20 days as positive control group.”
MethodGautier, A., Roussel, R., Lange, C., Piguel, X., Cauchi, S., Vol, S., Froguel, P., Balkau, B., & Bonnet, F. (2011) · Diabetes · doi:10.2337/db10-1442 · Cited by 13
Hyperglucagonemia in an animal model of insulin- deficient diabetes: what therapy can improve it?
Barbetti, F., Colombo, C., Haataja, L., CRAS-MÉNEUR, C. M. H., Bernardini, S., & Arvan, P. (2016) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-016-0029-5 · Cited by 14
“Following a drug administration protocol similar to that used to achieve glucose lowering in nonobese diabetic mice [30], Akita mice were treated with exendin-4 (10 nmol/kg body weight) or vehicle once a day for 13 days starting from the 3rd week of age.”
MethodPrevention and Reversal of Diabetes by All-Trans Retinoid Acid and Exendin-4 in NOD Mice
Juang, J., Van, Y.-H., Kuo, C.-H., Lin, M., Liu, Y.-H., & Chang, H.-Y. (2014) · International Journal of Endocrinology · doi:10.1155/2014/435481 · Cited by 12
“In addition, exendin-4 stimulates beta-cell growth and differentiation [8], inhibits beta-cell apoptosis [9], and delays the onset of diabetes [10].”
BackgroundVildagliptin/pioglitazone combination improved the overall glycemic control in type I diabetic rats
Abdelhamid, A. M., Abdelaziz, R. R., & Salem, H. A. (2018) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2017-0680 · Cited by 11
Treatment with sitagliptin exacerbates the M2 phenotype in macrophages in vitro
Quadros-Pereira, L., Nery-Neto, J. A. D. O., da Silva, E. M., Doretto-Silva, L., Yariwake, V. Y., Câmara, N. O. S., & Andrade‐Oliveira, V. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113730 · Cited by 11
Polymer-Based Delivery of Glucagon-Like Peptide-1 for the Treatment of Diabetes
Kim, P., & Kim, S. W. (2012) · ISRN Endocrinology · doi:10.5402/2012/340632 · Cited by 9
“According to report that GLP-1 receptors are detected in multiple cells within the immune system [13], GLP-1 or exendin-4 collectively suggests that current incretin therapies may have multiple beneficial effects in patients with type 1 diabetes, including improved glycemic control via multiple mechanisms.”
BackgroundAdipose Tissue, Hormones, and Treatment of Type 1 Diabetes
Gunawardana, S. C. (2012) · Current Diabetes Reports · doi:10.1007/s11892-012-0300-9 · Cited by 8
Structural study of an active analog of EX-4 in solution and micelle associated states
Wang, S., Yu, J., Li, W., & Li, F. (2010) · Biopolymers · doi:10.1002/bip.21566 · Cited by 7
Serum Levels of Incretin Hormones – GLP-1 and GIP in Patients with Type 1 Diabetes Mellitus
Stanchev, P. E., Orbetzova, M. M., Terzieva, D. D., Davcheva, D. M., Iliev, D. A., Petrov, S. V., Koleva, D. I., & Nonchev, B. (2019) · Folia Medica · doi:10.2478/folmed-2018-0056 · Cited by 7
Plummer, M. P., Meier, J. J., & Deane, A. M. (2013) · Critical Care · doi:10.1186/cc12758 · Cited by 6
“In animals, pharmacological administration of a GLP-1 agonist or dipeptidylpeptidase-4 (DPP-4) inhibitor (which inhibits GLP-1 degradation) is reported to aff ect immune modulation [3].”
BackgroundMessenger RNA delivery to islet β cells using conjugated lipid nanoparticles
Enriquez, J. R., Zhou, Z., Nelson, J. B., Huang, F., Figatner, K. T., Chakraborty, A., Pratuangtham, S., Xi, B., May, S. C., Tirrell, M., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102634 · Cited by 10
Wu, Y., Lu, Y., Yang, S., & Zhang, Q. (2021) · Journal of International Medical Research · doi:10.1177/03000605211066306 · Cited by 6
“Hadjiyanni et al.(31) reported that sustained GLP-1R activation delayed the onset of diabetes by preserving b-cell function in a murine model of T1DM.”
BackgroundThe Effects of DPP-IV Inhibition in NOD Mice with Overt Diabetes
Vargova, L., Zacharovová, K., Dovolilová, E., Vojtová, L., Cimburek, Z., & Saudek, F. (2013) · Folia Biologica · doi:10.14712/fb2013059030116 · Cited by 5
“proliferation and maintenance of peripheral regulatory T cells seems to be mediated through GLP1 receptor, as its mRNA was found in T cells in the spleen, thymus and lymph nodes of NOD mice (Hadjiyanni et al., 2008).”
BackgroundExendin-4 Exacerbates Burn-Induced Morbidity in Mice by Activation of the Sympathetic Nervous System
Ji, X.-J., Hao, J.-W., Li, G., Dong, N., Wang, X., Zhou, M., Zhang, Q., & Yao, Y.-M. (2019) · Mediators of Inflammation · doi:10.1155/2019/2750528 · Cited by 5
“Moreover, it could reduce the frequency of regulatory T cells (Tregs) in the thymus [13, 18], but it could increase in the spleen with a trend of enhanced suppression ability [19].”
BackgroundInfluentialRecent progress of remission in type 2 diabetes
Zhao, Z., Yue, H., Zhang, X., Chen, F., Xu, J., & Shao, S. (2025) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188251408210 · Cited by 4
“163 In addition, our previous research has shown that exenatide can ameliorate pancreatic islet β -cell dysfunction by restoring the balance of Th17/ Treg cells.”
Next-gen therapeutics to spare and expand beta-cell mass
Bolla, A. M., Usuelli, V., Nasr, M. B., Frigerio, S., Loretelli, C., D’Addio, F., & Fiorina, P. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.09.001 · Cited by 3
Lai, X., Luo, J., Luo, Y., Zheng, Y., Yang, H. M., & Zou, F. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107433 · Cited by 3
Post-Bariatric Surgery Hypoglycemia
Bantle, J. P. (2016) · The Endocrine Society eBooks · doi:10.1210/mtp5.9781943550043.ch43 · Cited by 3
Kero, J. T., Koskenniemi, J. J., Karsikas, S., Pokka, T. M.-L., Lou, O., Toppari, J., & Veijola, R. (2022) · Diabetic Medicine · doi:10.1111/dme.14913 · Cited by 2
Prevention of β-Cell Destruction in Autoimmune Diabetes: Current Approaches and Future Prospects
Sedimbi, S. K., & Sanjeevi, C. B. (2010) · Advances in experimental medicine and biology · doi:10.1007/978-90-481-3271-3_26 · Cited by 2
Effects of All-Trans Retinoid Acid and Exendin-4 on Islet Transplantation in NOD Mice
Juang, J., Kuo, C.-H., Liu, Y.-H., Chang, H.-Y., & Van, Y.-H. (2014) · Transplantation Proceedings · doi:10.1016/j.transproceed.2014.05.072 · Cited by 2
An overview of non-insulin adjunctive therapies for Type 1 diabetes
Ballav, C., & Gough, S. C. L. (2014) · Diabetes Management · doi:10.2217/dmt.14.38 · Cited by 2
Bokvist, K. B., Ding, Y., Landschulz, W. H., Sinha, V. P., Pastrak, A., & Belin, R. M. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13695 · Cited by 2
“In conclusion, based on promising preclinical data and our previous findings with [1-51] EGF plus TT223, we studied a combination of GLP-1RA and gastrin analogue for lasting, post-treatment glycaemic improvements in patients with T2DM.”
MethodGLP-1R is downregulated in beta cells of NOD mice and T1D patientsPreprint
Recino, A., Barkan, K., Schmidt-Christensen, A., Nilsson, J., Holmes, N., Howie, D., Holmberg, D., Larsson, P. G., Flodström‐Tullberg, M., Laraia, L., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/845776 · Cited by 2
“NOD mice reported a modest effect on diabetes incidence (18, 20).”
BackgroundWang, Y., He, S., Yang, H., Zhang, J., Yu, L., Xiong, J., Li, X., Qiu, J., & Ma, B. (2026) · Biology · doi:10.3390/biology15171472 · Cited by 1
Incretins: new targets for the prevention of diabetes and obesity
Neff, K., & le Roux, C. W. (2013) · Clinical Lipidology · doi:10.2217/clp.12.80 · Cited by 1
Exendin-4 Exacerbates Burn-Induced Mortality in Mice by Switching to Th2 Response
Hao, J.-W., Chen, Q., Liu, H., & Zhang, Q. (2022) · Journal of Surgical Research · doi:10.1016/j.jss.2022.07.029 · Cited by 2
Davanso, M. R. (2012) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.17.2012.tde-21062012-102848
Metadata
- Authors
- Hadjiyanni, I., Baggio, L. L., Poussier, P., & Drucker, D. J.
- Affiliations
- Mount Sinai Hospital (CA)
- Sunnybrook Health Science Centre (CA)
- Corresponding author
- Drucker, Daniel J.
- ORCID
- Drucker, Daniel J.
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2007-12-06
- Volume
- 149
- Issue
- 3
- Pages
- 1338-1349
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- PMC
- PMC2275367
- OpenAlex
- W2172277730
- Cited by
- 110
- References
- 34
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 5 · 2023: 1 · 2022: 7 · 2021: 3 · 2020: 2 · 2019: 9 · 2018: 3 · 2017: 2 · 2016: 5 · 2015: 2 · 2014: 9 · 2013: 11 · 2012: 10
- FWCI
- 5.02
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Endocrinology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- exendin-4, GLP-1 receptor, type 1 diabetes prevention, NOD mice, insulitis, beta-cell mass, glucose tolerance, regulatory T cells, CD4+ T cells, CD8+ T cells, diabetes onset
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Exenatide, Animals, Diabetes Mellitus, Experimental, Disease Models, Animal, Dose-Response Relationship, Drug, Female, Hypoglycemic Agents, Lymph Nodes, Peptides, Spleen, Venoms, CD4-Positive T-Lymphocytes, Mice, Inbred NOD, Receptors, Glucagon, CD8-Positive T-Lymphocytes, Disease Progression, Insulin-Secreting Cells, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.